INT84596

From wiki-pain
Revision as of 13:53, 24 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1999
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 8
Disease Relevance 8.49
Pain Relevance 0.60

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

aging (Aqp2) plasma membrane (Aqp2) protein complex (Aqp2)
transmembrane transport (Aqp2) lysosome (Aqp2) cytoplasm (Aqp2)
Anatomy Link Frequency
Kidney 4
duct 2
urine 2
Aqp2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
agonist 3 99.54 Very High Very High Very High
Clonidine 6 97.84 Very High Very High Very High
hyperexcitability 1 97.32 Very High Very High Very High
medulla 6 95.20 Very High Very High Very High
ischemia 2 40.52 Quite Low
anesthesia 21 25.00 Low Low
Neuritis 1 23.40 Low Low
antagonist 18 16.72 Low Low
isoflurane 24 5.00 Very Low Very Low Very Low
fibrosis 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Chronic Renal Failure 744 99.84 Very High Very High Very High
Aging 2 99.76 Very High Very High Very High
Hypertrophy 74 97.84 Very High Very High Very High
Polyuria 6 90.84 High High
Uremia 24 89.84 High High
Congenital Anomalies 8 69.52 Quite High
Disorders Of Creatine Metabolism 6 66.36 Quite High
Ocular Hypertension 75 45.12 Quite Low
Hypoxia 3 42.16 Quite Low
Injury 18 41.48 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This investigation focused on the possibility that this increase in free water clearance following administration of an alpha(2)-adrenoceptor agonist was associated with a reduction in medullary AQP-2 expression.
Negative_regulation (reduction) of Gene_expression (expression) of AQP-2 associated with agonist
1) Confidence 0.58 Published 1999 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 10525117 Disease Relevance 0 Pain Relevance 0.47
Kidney expression of AQP2 was decreased in CRF rats, both vehicle-treated (CRF-V) and candesartan-treated (CRF-C)
Negative_regulation (decreased) of Gene_expression (expression) of AQP2 in Kidney associated with chronic renal failure
2) Confidence 0.55 Published 2005 Journal Journal of Korean Medical Science Section Body Doc Link PMC2808601 Disease Relevance 1.90 Pain Relevance 0
Thus, these studies all provide firm evidence for the decreased of vasopressin-regulated water channel AQP2 expression and the significant defects in the collecting duct of the kidneys from CRF.
Negative_regulation (decreased) of Gene_expression (expression) of AQP2 in duct associated with chronic renal failure
3) Confidence 0.55 Published 2005 Journal Journal of Korean Medical Science Section Body Doc Link PMC2808601 Disease Relevance 0.81 Pain Relevance 0.05
The decreased AQP2 expression in CRF rats was not altered in response to candesartan treatment; 3) Candesartan treatment was associated with decreased NHE3 and TSC expression in CRF, which could be due to the Ang II AT1 receptor blockade and/or decreased aldosterone levels; and 4) BSC-1 expression was increased in both CRF groups and the increased expression of BSC-1 was more prominent in candesartan-treated CRF rats compared with vehicle-treated CRF rats.
Negative_regulation (decreased) of Gene_expression (expression) of AQP2 associated with chronic renal failure
4) Confidence 0.55 Published 2005 Journal Journal of Korean Medical Science Section Body Doc Link PMC2808601 Disease Relevance 1.28 Pain Relevance 0
Semi-quantitative immunoblotting of whole kidney protein samples from CRF rats (remnant kidney) and sham-operated rats (corresponding right whole kidney) demonstrated that CRF rats, both vehicle-treated (57±9% of sham-operated control level, p<0.05) and candesartan-treated (54±6% of sham-operated control level, p<0.05), had significantly decreased AQP2 expression compared with sham-operated controls (Fig. 3, Table 2).
Negative_regulation (decreased) of Gene_expression (expression) of AQP2 in kidney associated with chronic renal failure
5) Confidence 0.40 Published 2005 Journal Journal of Korean Medical Science Section Body Doc Link PMC2808601 Disease Relevance 1.66 Pain Relevance 0
Semiquantitative immunoblotting demonstrated decreased AQP2 expression in both CRF-C (54% of control levels) and CRF-V (57%), whereas BSC-1 expression was increased in both CRF groups.
Negative_regulation (decreased) of Gene_expression (expression) of AQP2 associated with chronic renal failure
6) Confidence 0.40 Published 2005 Journal Journal of Korean Medical Science Section Abstract Doc Link PMC2808601 Disease Relevance 1.91 Pain Relevance 0
In the present study, we further examine whether Ang II AT1 receptor blocker candesartan treatment in rats with CRF, where plasma vasopressin and AngII levels are elevated, could alter the downregulation of renal AQP2 expression and decreased urine concentration which were already seen in CRF rats (7).
Negative_regulation (downregulation) of Gene_expression (expression) of AQP2 in urine associated with chronic renal failure
7) Confidence 0.40 Published 2005 Journal Journal of Korean Medical Science Section Body Doc Link PMC2808601 Disease Relevance 0.73 Pain Relevance 0.04
In addition, the expression of several aquaporins including AQP1, AQP2, AQP3, and AQP5 decrease with aging [49–51], and therefore AQP4 expression may also decrease with aging.
Negative_regulation (decrease) of Gene_expression (expression) of AQP2 associated with aging
8) Confidence 0.29 Published 2008 Journal Molecular Vision Section Body Doc Link PMC2559817 Disease Relevance 0.20 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox